mCRC
Dec 01, 2025
The Next Wave of Metastatic Colorectal Cancer Drug Treatment: 6 Therapies Poised to Change the Landscape
The metastatic colorectal cancer drug treatment landscape has advanced considerably, with a growing range of targeted therapies, immunotherapies, and innovative agents now complementing standard chemotherapy. The mCRC treatment paradigm is structured across multiple lines of therapy. First-line (1L) treatment typic...
Read More...
May 30, 2023
FDA Approves Lexicon’s INPEFA (Sotagliflozin); PTC Therapeutics’s Vatiquinone MOVE-FA Registration-Directed Trial; EU Approval to Novartis’s Sickle Cell Disease Drug; EMA Approves Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC; FDA Grants Priority Review to Fruquintinib for mCRC; FDA Orphan Drug Designation to Vega Therapeutics’s VGA039
Lexicon Announces FDA Approval of INPEFA (Sotagliflozin) For Treatment of Heart Failure Lexicon Pharmaceuticals, Inc. announced that the FDA has approved INPEFATM (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure vis...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
